TOCILIZUMAB

Oct. 26, 2020

A recent study suggests that the drug tocilizumab may not prevent mortality in Covid-19 patients. It is the second such study on this drug.

About:

  • Tocilizumab is the second drug, after hydroxychloroquine, that had quickly earned global popularity as a Covid-19 treatment before its efficacy came under question in the wake of poor trial outcomes.

  • Tocilizumab is an immunosuppressant, commonly used for rheumatoid arthritis, and marketed as Actemra by Swiss pharma company Roche. It was repurposed in January to fight severe lung infection in Covid-19 patients.